Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

Konstantinos Dimopoulos, MD, Peter Gimsing, MD PhD, Gangning Liang, Kirsten Grønbæk, Alexandra Helbo Søgaard, Ranjani Lakshminarasinham

Blood (2016) 128 (22): 3258.

https://doi.org/10.1182/blood.V128.22.3258.3258

Published: 2016

Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Blood (2015) 126 (23): 727.

https://doi.org/10.1182/blood.V126.23.727.727

Published: 2015

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Marita Westhrin, MSc, Siv Helen Moen, PhD, Toril Holien, PhD, Oddrun Elise Olsen, MSc, Anne Kærsgaard Mylin, MDhD, Peter Gimsing, MD PhD, Ingemar Turesson, MD PhD, Anders Waage, MD PhD, Therese Standal, PhD

Blood (2014) 124 (21): 2065.

https://doi.org/10.1182/blood.V124.21.2065.2065

Published: 2014

Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1986.

https://doi.org/10.1182/blood.V122.21.1986.1986

Published: 2013

Journal Articles

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Torben Plesner, MD, Henk Lokhorst, MD, PhD, Peter Gimsing, MD, PhD, Hareth Nahi, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2012) 120 (21): 73.

https://doi.org/10.1182/blood.V120.21.73.73

Published: 2012

Journal Articles

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

Meral Beksac, MD, Anders Waage, MD, PhD, Sara Bringhen, MD, Sigurdur Y Kristinsson, MD PhD, Gulsan Sucak, MD, Peter Gimsing, MD, PhD, Lupparelli Giulia, PhD, Tulin Firatli Tuglular, MD, Gunnar Juliusson, MD PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3970.

https://doi.org/10.1182/blood.V118.21.3970.3970

Published: 2011

Journal Articles

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Peter Gimsing, MD, DMSci, Assoc. Prof., Torben Plesner, MD, Hareth Nahi, Henk Lokhorst, MD, PhD, Marie-Louise Valentin, MD, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2011) 118 (21): 1873.

https://doi.org/10.1182/blood.V118.21.1873.1873

Published: 2011

Journal Articles

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Peter Gimsing, MD, DMSci, Assoc. Prof., Oyvind Hjertner, Niels Abildgaard, Niels Frost Andersen, Tobias Gedde Dahl, Henrik Gregersen, MD, Ulf-Henrik Mellqvist, MD, PhD, Olle Linder, Roald Lindas, Niels-Aage Tøfner Clausen, Stig Lenhoff

Blood (2011) 118 (21): 3073.

https://doi.org/10.1182/blood.V118.21.3073.3073

Published: 2011

Journal Articles

Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group).

Peter Gimsing, MD, Kristina Carlson, MD, Peter Fayers, Ingemar Turesson, MD, Finn Wisløff

Blood (2007) 110 (11): 533.

https://doi.org/10.1182/blood.V110.11.533.533

Published: 2007

Journal Articles

Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.

Anders Waage, MD, Peter Gimsing, MD, Gunnar Juliusson, MD, Ingemar Turesson, MD, Peter Fayers, PhD

Blood (2007) 110 (11): 78.

https://doi.org/10.1182/blood.V110.11.78.78

Published: 2007

Journal Articles

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Daniel Sullivan, MD, Seema Singhal, MD, Michael Schuster, MD, James Berenson, MD, Peter Gimsing, MD, Finn Wislöff, MD, Anders Waage, MD, Melissa Alsina, MD, Robert Gerwien, PhD, Anne Clarke, RN, MPH, Karen Moller, Chean Eng Ooi, PhD

Blood (2006) 108 (11): 3583.

https://doi.org/10.1182/blood.V108.11.3583.3583

Published: 2006

Journal Articles

Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.

Peter Gimsing, MD, Frank Wu, PhD, Xiaozhong Qian, PhD, Michael Jeffers, PhD, Lene Knudsen, MD, Maxwell Sehested, MD, PhD, Henri S. Lichenstein, PhD

Blood (2005) 106 (11): 3337.

https://doi.org/10.1182/blood.V106.11.3337.3337

Published: 2005

Journal Articles

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Peter Gimsing, MD, Jon Magnus Tangen, MD, Jan Westin, MD

Blood (2004) 104 (11): 924.

https://doi.org/10.1182/blood.V104.11.924.924

Published: 2004

NARROW

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group).

Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only